SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle shares are trending as traders react to the sudden cancellation of Chairman Larry Ellison’s plan to sell millions of shares, which the community widely views as a bullish catalyst to reverse recent weakness. While many investors are optimistic about a potential short squeeze and a rebound toward higher price levels, a vocal minority remains focused on fundamental concerns regarding the company's high capital expenditure, debt levels, and the sustainability of AI-related revenue growth.

the cat on Base  community-run home for $BASECAT

Basecat

The community is actively debating the price action of Basecat as it experiences high volatility following its recent listing on Coinbase. While some traders view current dips as accumulation opportunities for a potential reversal, others express skepticism, cautioning against the risks of a classic pump-and-dump cycle.

Hunter Biden’s Laptop (LAPTOP) is a memecoin referencing the eponymous Hunter Biden laptop sensation that’s been a fixture in global media news cycles for the past six years. LAPTOP is a fungible, freely transferable, non-yield-bearing ERC-20 token on Base. As a memecoin, LAPTOP has no utility, but incorporates two novel distribution mechanics designed to promote long-term community growth: a large community airdrop and an event-based supply mechanism.

Hunter Biden's Laptop

The asset is experiencing a severe decline following a rapid price collapse that many in the community are characterizing as a market rug pull. Traders are debating the legitimacy of the token and the nature of the project's launch, with many expressing skepticism and mocking the rapid loss of value.

VeChain is a public Layer-1 blockchain designed for real-world applications. Founded in 2015, its VeChainThor network supports enterprise and consumer use cases involving supply chains, product provenance, sustainability, digital product passports, tokenized incentives and verifiable data.  VeChainThor combines EVM-compatible smart contracts with a dual-token model, native fee delegation and multi-clause transactions. VET is the network’s native asset and staking collateral, while VTHO is used to pay transaction fees and execute smart contracts.  VeChain’s ecosystem includes VeBetter, an app platform that rewards verified positive actions; StarGate, its NFT-based staking platform; VeWorld, its self-custody wallet; and VeWorld.ai, its AI-agent platform. In its April 2026 roadmap, VeChain reported that VeBetter had reached 5.3 million users, more than 50 live applications and over 50 million verified actions.  VeChain has also worked with organizations including Walmart China, DNV, PwC, Boston Consulting Group and UFC across enterprise, sustainability and consumer initiatives.

Vechain

Vechain is currently trending due to a combination of general market volatility, frustration over stagnant price action compared to other assets, and ongoing speculation regarding future network utility and price recovery. Investors are divided between those who are bearish due to long-term underperformance and those who remain optimistic, often citing potential institutional adoption and upcoming technical developments as catalysts for a long-term turnaround.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The community is focused on the potential for upcoming clinical catalysts and the broader integration of ImmunityBio's technology into global cancer care protocols, following recent discussions around international partnerships and a new patent application. While many traders remain bullish on the long-term potential of Anktiva and the company's manufacturing capacity, others express frustration over persistent price volatility and the impact of short selling on the stock's valuation.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Crude oil is trending due to volatile fluctuations driven by shifting geopolitical tensions in the Middle East and ongoing uncertainty regarding U.S.-Iran diplomatic relations. Traders remain divided, with some betting on a continued rally amid supply concerns and military actions, while others anticipate price declines based on reports of recovering export traffic and broader market oversupply.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

The conversation surrounding Polkadot is fragmented, with community members expressing frustration over consistent price declines and low user demand, while others argue for long-term potential based on the Polkadot 2.0 upgrade and ecosystem developments. Many participants remain divided between those viewing the asset as a "dead" project and those continuing to accumulate through staking in anticipation of a future market recovery.

BNB is the native utility token of the BNB Chain ecosystem, acting as a multi-chain asset that powers decentralized applications and facilitates value exchange across its network. It serves as the primary asset for paying transaction gas and smart contract deployment fees while providing users with tiered fee discounts on the Binance exchange. The project’s main value proposition lies in its unified multi-chain architecture, which integrates a smart contract platform, a Layer 2 scaling solution, and a decentralized data storage network into a cohesive settlement and data availability layer.  The network operates on a Proof of Staked Authority consensus mechanism, utilizing a group of 21 active validators known as the Cabinet to verify transactions and produce blocks every 3 seconds. Validators are elected daily based on the amount of BNB staked or delegated to them, and the system employs fast finality and slashing penalties to maintain security and integrity. To manage its long-term economy, the project uses a programmatic dual-burn strategy that permanently removes tokens through real-time fee destruction and quarterly buybacks.  Launched in 2017 by the Binance platform, the project initially distributed 50% of its 200 million token supply to the public, while the founding team received 40% and angel investors were allocated 10%. Though it began as a token on the Ethereum network, it eventually migrated to its own autonomous architecture that remains fully compatible with the Ethereum Virtual Machine. Today, the token's utility includes paying for network gas, participating in staking rewards, and enabling decentralized governance through which holders can vote on technical upgrades and economic changes.

Binance

BNB is currently in the spotlight as bulls monitor a key resistance zone following a rebound, while the community remains divided between technical momentum and aggressive shorting sentiment. Traders are debating potential breakout levels as broader market conditions and institutional activity continue to drive active discussion.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences shares declined following a sharp increase in short selling and volatility, which traders attribute to market manipulation, coordinated sentiment shifts on social media, and anxiety over a prolonged quiet period. While some investors fear the trial's duration signals underlying issues, long-term holders maintain that the survival data delay reflects the drug's efficacy and are awaiting formal trial results.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is experiencing significant volatility as investors debate whether the recent sharp decline following strong earnings results represents an attractive buying opportunity or a deeper correction. Traders are closely monitoring key support levels near $160 and expressing frustration over the stock's inability to sustain upward momentum amid broader market concerns and concerns over potential S&P 500 exclusion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vaxcyte announced the appointment of two senior executives and provided a more specific timeline for data from its VAX-31 pneumococcal vaccine program. The clinical-stage vaccine company named Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer. It also expects preliminary safety, tolerability and immunogenicity data from the Phase 3 OPUS-1 trial in adults by the end of October 2026, narrowing its previous guidance to the fourth quarter. 
Jodar joins from Pfizer, where he spent 17 years and most recently served as Senior Vice President and Chief Medical Officer for Vaccines and Infectious Diseases, overseeing programs including Prevnar 13, Prevnar 20, Abrysvo, Comirnaty and Paxlovid. McAvoy brings more than 30 years of biopharmaceutical legal experience, most recently as Teva’s Executive Vice President and Chief Legal Officer, after senior roles at Endocyte and Eli Lilly. 
 $PCVX

StockTwits Web

Vaxcyte Inc

Vaxcyte announced the appointment of two senior executives and provided a more specific timeline for data from its VAX-31 pneumococcal vaccine program. The clinical-stage vaccine company named Luis Jodar as Chief Medical Officer and David McAvoy as Chief Legal Officer. It also expects preliminary safety, tolerability and immunogenicity data from the Phase 3 OPUS-1 trial in adults by the end of October 2026, narrowing its previous guidance to the fourth quarter. 
Jodar joins from Pfizer, where he spent 17 years and most recently served as Senior Vice President and Chief Medical Officer for Vaccines and Infectious Diseases, overseeing programs including Prevnar 13, Prevnar 20, Abrysvo, Comirnaty and Paxlovid. McAvoy brings more than 30 years of biopharmaceutical legal experience, most recently as Teva’s Executive Vice President and Chief Legal Officer, after senior roles at Endocyte and Eli Lilly. 
 